Latest "Advanced BioAnalytical Services Incorproated (Advion Biosciences)" News Stories

06:21 EST 18th January 2019 | BioPortfolio

Here are the most relevant search results for "Advanced BioAnalytical Services Incorproated (Advion Biosciences)" found in our extensive news archives from over 250 global news sources.

More Information about Advanced BioAnalytical Services Incorproated (Advion Biosciences) on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Advanced BioAnalytical Services Incorproated (Advion Biosciences) for you to read. Along with our medical data and news we also list Advanced BioAnalytical Services Incorproated (Advion Biosciences) Clinical Trials, which are updated daily. BioPortfolio also has a large database of Advanced BioAnalytical Services Incorproated (Advion Biosciences) Companies for you to search.

Showing "Advanced BioAnalytical Services Incorproated Advion Biosciences" News Articles 1–25 of 17,000+

Friday 18th January 2019

Selvita (SLV) - SEL120 to enter clinical development in 2019

Edison Investment Research - Pharmaceuticals & healthcare - Selvita: The data readout from the SEL24 Phase I/II trial in relapsed/refractory AML and the second lead asset, SEL120, moving into clinical development next year are milestones in Selvita’s internal drug R&D. This should accelerate, as the company’s plans to focus on innovation were endorsed by shareholders during the fun...

Global Blood Group Typing Market 2019-2023 | 10% CAGR Projection over the Next Four Years | Technavio

The global blood group typing market is expected to post a CAGR of nearly 10% during 2019-2023, according to the latest market research report by Technavio. This press release features multimedia. View the full release here:

MabPlex, a China Biologic CDMO, Closes $59 million Series A

MabPlex, a biologics CDMO located in Yantai, raised $59 million in a Series A round from SDIC Venture Fund and Shenzhen Venture Capital, two state-owned investors. Founded in 2013, MabPlex offers biologics development and manufacturing services, including mAbs, recombinant proteins, ADCs and bispecifics. Its offerings range from gene sequencing to cell line development and commercial production. M...

Emerson launches new training solution

New Performance Learning Platform provides training to current and future workers on advanced instrumentation and control technologies using real plant-like process

ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been The post ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors appeared first on Pharmaceutical Business review.

Fresenius Medical Care launches 4008A dialysis machine tailored to needs in emerging markets

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous 18.01.2019 / 08:02 The issuer is solely responsible for the content of this announcement. Fresenius Medical Care, the world's largest provider of dialysis products and services, today announced the launch of its 4008A dialysis machine, which was especially designed to meet the needs of emerging markets. With th...

Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine

COPENHAGEN, Denmark, January 18, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN® smallpox vaccine. The option, valued at USD 44 million, will cover qualification of the new fill-finish facility, currentl...

Thursday 17th January 2019

TrakCel and Quick partner to provide industry-leading digital supply chain IT solution for cell and gene therapies

Platform enhances visibility and performance of the entire personalized medicine process – from the initial sample collection to final patient treatment NEW YORK (PRWEB) January 17, 2019 TrakCel, the leading cell and gene therapy supply chain tracking and orchestration system software developer, and The Quick Life Science Group (Quick Healthcare and QuickSTAT) today announce a partnership to of...

QUOTED. Jan. 18, 2019. George Savage.

Proteus Digital Health announced a new partnership with Minneapolis-based Fairview Health Services and the University of Minnesota Health to prescribe...   

Teladoc Launches Personalized Back Care Solution to Expand Portfolio of Offerings

Today Teladoc Health announced the U.S. launch of Teladoc Back Care – a personalized, online back pain treatment program to reduce the intensity, frustration, and impact of back pain. This new service adds to Teladoc Health’s broadening array of services, ranging from cold and flu to complex conditions like behavioral health, and even cancer. With back pain estimated to ... Read More

Proteus Digital Health introduces digital medicines for cancer

In collaboration with Fairview Health Services and University of Minnesota Health in the US, Proteus Digital Health has launched digital...Read More... The post Proteus Digital Health introduces digital medicines for cancer appeared first on Pharmaceutical Technology.

New DNA sequencer installed at Harry Perkins Institute

The Harry Perkins Institute of Medical Research (HPIMR) has installed an Illumina NovaSeq 6000 DNA sequencer as part of the Australian Cancer Research Foundation (ACRF) Centre for Advanced Cancer Genomics. The sequencer will be housed at the single-cell sequencing facility being led by Professor Alistair Forrest at the HPIMR, on behalf of a consortium of cancer researchers from across Perth. Las...

Bill Wilson Center Joins Uplift Family Services

Bill Wilson Center, a leader in homeless services for youth and young families in Santa Clara County, is becoming an agency of Uplift Family Services, one of the largest, most comprehensive mental and behavioral health treatment programs in California. BWC shall convert to a California member-based nonprofit public benefit corporation with Uplift ...

Servier and Taiho Oncology Present Latest LONSURF® (trifluridine/tipiracil) Data at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today that the safety and efficacy data in the gastrectomy patient subgroup of the global Phase III trial TAGS evaluating LONSURF® (trifluridine/tipiracil, TAS-102) in patients with metastatic gastric cancer (mGC) are consistent with the over...

Qualifying for Social Security Disability Benefits With Cancer

Denise Brock, Operations DirectorThis article was provided by Disability Benefits Help, an independent organization dedicated to helping people of all ages get Social Security disability benefits. If you have any questions on how to qualify for disability benefits, you can reach out to their team at or yo

Adaptive Biotechnologies Announces Medicare Coverage of the clonoSEQ® Assay for MRD Testing in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia at Multiple Timepoints Throughout Treatment and Remission

Adaptive Biotechnologies, an immune driven-medicine company, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) and leader in assessing diagnostic technologies through its MolDX program, has established coverage of the clonoSEQ® Assay for Medicare patients with multiple myeloma and B-cell acute lymphoblastic leukemia (ALL). clon...

Dorsey Adds Experienced Litigator Anthony Badaracco in New York

International law firm Dorsey & Whitney LLP announced today that Anthony P. Badaracco has joined the Firm’s Commercial Litigation Group as Of Counsel in Dorsey’s New York office. This press release features multimedia. View the full release here: Anthony P. Badaracco has joined D

MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study 17.01.2019 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, January 17, 2019   MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis   MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDA...

Pulse Biosciences Announces Two Appointments Focused on CellFX™ Commercialization: Promotion of Edward Ebbers and Addition of Robert Tyson

− Ebbers named Executive Vice President and General Manager, Dermatology − Tyson named Vice President, Sales North America Pulse Biosciences, Inc. (NASDAQ:PLSE), a medical technology company bringing to market its proprietary CellFX™ System, today announced the promotion of Edward Ebbers to Executive Vice President and Gen...

Physician claims he lost work after Montana hospital monopolized cardiology services

Interventional cardiologist Kipp Webb and representatives from Montana’s Bozeman Health Deaconess Hospital entered a 19-day jury trial Jan. 17 after Webb claimed the hospital created a monopoly over cardiology services in 2011, preventing him from practicing in the area.

How advanced HF patients and their caregivers can ensure a favorable QoL

The nature of caregiving means the caregiver-patient relationship is always changing, but continued support from a network of experts and dedication to mutuality and preparedness can ensure both patients and caregivers have a good quality of life (QoL), according to a study published Jan. 14 in Circulation: Cardiovascular Quality and Outcomes.

National Dental Now Offers Leading, Full-Arch Dental Implant Solution, Teeth Tomorrow®, at All Locations

Respected dental team, National Dental, now offers the leading, full-arch dental implant solution, Teeth Tomorrow®, at each of their 10 locations. WILLISTON PARK, N.Y. (PRWEB) January 17, 2019 National Dental now welcomes patients to experience the life-changing benefits of the full-arch dental implants solution, Teeth Tomorrow®. Always striving to offer the latest dental treatments wit...

FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Mar. 26-27, 2019, Princeton, NJ

CAPA failures show up in half of all warning letters. Register today for this 2-day CAPA workshop. FALLS CHURCH, Va. (PRWEB) January 17, 2019 Conducting Advanced Root Cause Analysis CAPA Investigations: Critical Thinking Skills and Innovative Techniques to Improve Inspections **Presented by FDAnews and Learning Plus** Mar. 26-27, 2019 – Raleigh, NC The greatest th...

New Leaders Join CDISC 2019 Board of Directors

CDISC today announced three new members have joined its Board of Directors. Dr. Pandu Kulkarni, Dr. Hiroshi Masumoto, and Dr. Zhengqing Li each began serving a three-year term at the beginning of the year. Dr. Pandu Kulkarni is the Chief Analytics Officer and Vice President of Biometrics and Advanced Analytics at Eli Lilly and Co. Dr. Kulkarni lea...

Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that a poster entitled “Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric/GEJ Ca

Quick Search


News Quicklinks